GB1565581A

GB1565581A - Pyridine derivatives

Info

Publication number: GB1565581A
Application number: GB435477A
Authority: GB
Original assignee: John Wyeth and Brother Ltd
Current assignee: John Wyeth and Brother Ltd
Priority date: 1977-02-02
Filing date: 1977-02-02
Publication date: 1980-04-23

Description

(54) PYRIDINE DERIVATIVES (71) We, JOHN WYETH & BROTHER LIMITED, a British Company of Hunter combe Lane South, Taplow, Maidenhead, Berkshire SL6 OPH, do hereby declare the invention for which we pray that a patent may be granted to us and the method by which it is to be performed, to be particularly described in and by the following statement: The invention relates to novel pyridine derivatives which show pharmaceutical activity, particularly CNS activity. The invention provides the new pyridine derivatives, processes for their preparation and pharmaceutical compositions containing the new pyridine derivatives.

The invention provides novel pyridine derivatives having the formula I

and their pharmaceutically acceptable acid addition salts, wherein R1 and R2 together represent --Arll-(lower allrylenet-Ar2-- where Arl and Ar2 are independently arylene or heteroarylene, or when R1 and R2 are separate one of R1 and R2 represents aryl or heteroaryl and the other other one of R1 and R2 represents aryl, heteroaryl, ar(lower)alkyl or lower alkyl, R3 and R4 are independently hydrogen or lower alkyl and n represents 0 or 1. The invention particularly includes those cases where R1 and R2 are independently aryl or heteroaryl whilst n is 0.

By the term "lower" as used herein in connection with such groups as allyl, alkylene and alkoxy, there is meant that the group contains up to 6 carbon atoms, preferably up to 4 carbon atoms. By the term "aryl or heteroaryl" there is meant a monovalent group having aromatic character. By the term "arylene or heteroarylene" there is meant a divalent group having aromatic character. The groups having aromatic character may be carbocyclic or heterocyclic and the aromatic ring or rings may be unsubstituted or carry one or more substituents.

R1 and R2 may be the same or different aromatic groups. Examples of aryl groups include phenyl; naphthyl phenyl substituted by one or two substituents, for example, halogen, for instance, fluorine, chlorine or bromine; lower alkyl, for instance, methyl, ethyl, propyl or butyl; lower alkoxy, for instance methoxy, ethoxy, propoxy or butoxy; lower alylenedioxy, for instance methylenedioxy and trihaloalkyl, for instance, trifluoromethyl.

The aryl group preferably has a monocyclic aromatic ring but may be bicyclic, for instance, naphthyl or naphthyl carrying one or more substituents, for example, those mentioned above in connection with substitution of phenyL Examples of heteroaryl groups include furyl (for example, 3-furyl), thienyl (for example, 2-thienyl), oxazolyl, thiazolyl, benzthiazolyl, pyridyl (for example 2- and 4pyridyl), quinolyl (for example 2-quinolyl) and isothiazolyl (for example, 5-isothiazolyl). The heteroaryl groups may be unsubstituted or substituted as described above for the substitution of phenyl. Preferred heteroaryl groups are thienyl, pyridyl and furyl.

One of R1 and R2 may be an aryl or heteroaryl group as described above whilst the other of R1 and R2 may be lower alkyl, for example, methyl, ethyl, propyl, butyl or pentyl, or ar(lower)alkyl, for instance, phen(lower) alkyl, e.g. benzyl or phenethyl. When Rl and R2 are connected together the two arylene or heteroarylene groups may be the same or different The groups may be divalent groups corresponding to the aryl and heteroaryl groups particularly described above, for instance, phenylene. The lower alkylene group may be, for example, methylene, ethylene or trimethylene. The preferred meanings of R' and R2 are as follows. One of Rl and R2 is phenyl, (lower alkyl)phenyl, (lower alkoxy)phenyl, halophenyl, thienyl or pyridyl whilst the other of Rl and R2 is phenyl, (lower alky1)phenyl, (lower alkoxy)phenyl, halophenyl, thienyl, pyridyl, phen(lower)alkyl or lower alkyl or Rl and R2 together represent -phenylene-(lower alkylene)-phenylene-.

R3 and R4 may be the same or different and are selected from hydrogen and lower alkyl, for example, methyl, ethyl, propyl and butyl. R3 and R4 are preferably chosen from hydrogen and methyl.

The acid addition salts may be formed from inorganic acids and organic acids and examples include the sulphate, hydrochloride, hydrobromide, hydroiodide, nitrate, phosphate, sulphonate (such as the methane sulphonate and toluene-p-sulphonate), acetate, maleate, fumarate, tartrate and format.

It will be apparent to the reader that the compounds having formula I where R' and R2 differ possess an asymmetric carbon atom and thus exhibit the property of optical isomerism.

The invention includes the individual optical isomers as well as the racemic mixtures. The racemates may be resolved into individual optical isomers in known manner.

The compounds of general formula I and their acid addition salts can be prepared in a number of ways by building up the molecule from suitable starting materials in known manner. A choice of methods exists so that the most appropriate one may be chosen in each case. In particular the compounds may be prepared by reduction of amides, conversion of primary amines into secondary amines or conversion of secondary amines into tertiary amines, by reaction of an organometallic com pound with Schiff's bases, by reaction of benzilic acid with aminopyridines and by reduction of Schiff > s bases.

The invention provides a process for the preparation of a compound having formula I or a pharmaceutically acceptable acid addition salt thereof, wherein (a) a compound having the formula III

(wherein Rl and R2 are as defined above, preferably phenyl or the like) is reacted under elevated temperature with a 4-aminopyridine having the formula IV

(where R" is as defined above) to form a compound having the formula

(where R1, R2 and R4 are as defined above); or (b) a compound having the formula

(where R' and R4 are as defined above) is treated with a reactive organometallic compound whose organo moiety is R2 as defined above; or (c) an amine having the formula VII

or a salt thereof, is reacted with a compound having formula VIII Y--Z (VIII) (where Z is a replaceable atom or group) to form an amine having the formula IX

as a free base or acid addition salt (where in formulae VII, VIII and IX any one of W, X and Y represents a group having the formula

(where R', R2 and n are as defined above), another one of W, X and Y represents a group having the formula

(where R4 is as defined above) and the remaining one of W, X and Y represents R" as defined above subject to the proviso that, when Y represents R3 as defined above, then R" is lower alkyl); or (d) a Schiff's base having the formula XII or XIII

(wherein Rl, R' and R4 are as defined above) is reduced; or (e) an amide having the formula XIV

or an acid addition salt thereof (wherein Rl, R, R3 and R4 are as defined above) is reduced to form a compound where n is 1. Where desired, the process may include conversion of a free base form of the compound having formula I into a pharmaceutically acceptable acid addition salt thereof or conversion of an add addition salt form of a compound having formula I into its free base form.

Where it is desired to form an end product in which R1 or R2 contains a reactive group, the group may be protected in the starting material, i.e. R' represents a protected form of R1 or R2 represents a protected form of R2.

For example, where R' or R2 represents amine phenyl, the starting material may contain a protecting group for the amino function. Many protecting groups will suggest themselves to those skilled in the art. When a protecting group is employed we prefer to use one which can be removed under mild conditions.

The starting materials for methods (a), (b) and (c), namely those having formulae III, IV, VI, VII and VIII and the reactive organometallic compound are sometimes known and, where new, can be prepared in known manner.

The compounds having general formula XIV and their acid addition salts are new compounds also provided by the invention. They can be prepared in manner known per se. In particular an amine having the formula

(where R and R4 are as defined above) is acylated to introduce the acyl defined group

(where K1 and R2 are as defined above).

The acylation may be performed using the acid halide, for instance, the acyl chloride or acyl bromide, in the presence of a suitable base. The Schiff's bases of formulae XII and XIII are sometimes known [see, for example, Chemical Abstracts (1972), 77, 88002a] or, if new, obtainable in known manner.

We prefer to carry out method (a) by using benzilic acid as the compound having formula III. The reaction is preferably carried out by heating the reactants at an appropriate temperature, which may be 180"C to 230"C, in the absence of a solvent.

The compounds having the formula VI are Schiff's bases which can be prepared in known manner by condensation of an aldehyde of formula R'CHO with an amine having formula IV. Method (b) is preferably carried out by using a compound having the formula R2Li as the organometallic compound. Alternatively a Grignard reagent such as phenyl magnesium bromide may be employed.

The reaction is preferably carried out in an inert solvent such as diethyl ether under an inert atmosphere such as nitrogen. The reaction yields an amine having formula V in the form of a salt such as the lithium salt. Decomposition of the resulting reaction complete with ice water or a cold solution of ammonium chloride gives the amine which can be recovered in standard manner.

Method (c) can be carried out using known procedures for converting primary amines into secondary amines and secondary amines into tertiary amines. We prefer to use a compound of formula VIII in which Z is halogen, particularly bromine or chlorine.

The starting amine may be used as such or in the form of a salt thereof, for instance, the lithium salt. An example of the use of the salt is as follows: An organometallic com pound such as the lithium salt having the formula R2Li is reacted with a Schiffs base having formula VI to give a compound having the formula V in the form of its lithium salt having the formula XVII

This procedure may be carried out as described under method (b). However instead of treating the salt with water as in method (b) the lithium salt is treated with a lower alkyl halide, for-example, methyl chloride or ethyl bromide, to effect alkylation to result in a tertiary amine in which R3 is lower alkyl.

Method (c) may also be used to form secondary amines. For example a compound having the formula W-NH, may be treated with a compound having formula Y-Z (where one of W and Y represents a group having formula X and the other represents a group having formula XI) to form a secondary amine of formula W-NH-Y. We prefer to carry out this method by reacting an appropriately substituted methyl halide of formula XVIII

(where Hal is halogen such as chlorine or bromine and n is 0 or 1) with an amine having the formula IV.

The reaction of the amine having formula VII with the compound having formula VIII may be carried out under elevated temperature in a suitable solvent, for example, toluene.

The reduction according to method (d) may be carried out under conditions known for the reduction of Schiff's bases to form amines. As reducing agent there may be used lithium aluminium hydride or sodium borohydride. In particular, the reduction may be performed using sodium borohydride in an alcohol, for instance, methanol or ethanol, at room tem erature. The reduction may also be carried out using lithium aluminium hydride in diethyl ether at room temperature or under reflux.

Catalytic hydrogenation may be used. The reduction conditions employed should be so chosen as to avoid reduction of the pyridine ring and/or cleavage of the di(aryl or hetero aryl)methyl group QHRIR-. K2.

It will be appreciated that where R1 or R2 in the starting products contains a reducible group, this may be reduced under the reaction conditions, for example, a nitrophenyl group may be reduced to aminophenyl.

It will be appreciated that the reduction products obtained from Schiff's bases of formula XII are compounds where n is 0 and R3 is hydrogen and those obtained from Schiff's bases of formula XIII are compounds where n is 1 and R3 is hydrogen.

The reduction according to method (e) may be carried out under conditions known for the reduction of amides to form amines. As reducing agent there may be used lithium aluminium hydride or diborane. It will be appreciated that the reduction products obtained are compounds where n is 1.

When a product of formula I has been prepared in the form of its free base this may be converted into an acid addition salt by addition of an acid. For example, ethereal hydrogen bromide or ethereal hydrogen chloride may be added to a solution of the free base to give the hydrobromide or hydrochloride salt respectively. Acid addition salt forms of compounds having formula I may be converted into the free base form in known manner, in particular, by addition of a base.

The compounds having formula I and their pharmaceutically acceptable acid addition salts are indicated for pharmaceutical use. In particular they show cNS (central nervous system) activity, when tested on warm blooded animals.

They reverse the hypothermia induced by reserpine on mice and thus may have potential use as antidepressant drugs. Some show stimulant activity. For example, the compound of Examples 1 and 2 exhibited stimulant activity in mice when tested at doses of 1.27 and 4 milligrams per kilogram administered orally and intraperitoneally.

The invention also includes pharmaceutical compositions containing as active ingredient a compound of formula I or a pharmaceutically acceptable acid addition salt thereof which may be micronised if desired. In addition to the active ingredient said compositions also contain a pharmaceutically acceptable carrier. Any suitable carrier known in the art can be used to prepare the pharmaceutical compositions.

In such a composition, the carrier may be a solid, liquid or mixture of a solid and a liquid.

Solid form compositions include powders, tablets and capsules. A solid carrier can be one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, binders or tablet-disinte- grating agents; it can also be an encapsulating material. In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from 5 to 99, preferably 1080?o' by weight of the active ingredient. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, and cocoa butter. The term "composition" is intended to include the formulation of an active ingredient with an encapsulating material as carrier to give a capsule in which the active ingredient (with or without other carriers) is surrounded by carrier, which is thus in association with it.

Similarly cachets are included.

Sterile liquid form compositions include sterile solutions, suspensions, emulsions, syrups and elixirs. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable sterile liquid carrier, such as sterile water, a sterile organic solvent or a mixture of both. Preferably a liquid carrier is one suitable for parenteral injection. Where the active ingredient is sufficiently soluble it can be dissolved in a suitable organic solvent, for instance aqueous propylene glycol or polyethylene glycol solutions. Aqueous propylene glycol containing from 10 to 75 % of the glycol by weight is generally suitable. In other instances compositions can be made by dispersing the finelyaivided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution, or in a suitable oil, for instance arachis oil. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be be utilised by intramuscular, intraperitoneal or subcutaneous injection. In many instances a compound is orally active and can be administered orally either in liquid or solid composition form.

Preferably the pharmaceutical composition is in unit dosage form. In such form, the composition is sub-divided in unit doses containing appropriate quantities of the active ingredient; the unit dosage form can be a packaged composition, the package containing specific quantities of compositions, for example, packeted powders or vials or ampoules. The uni.

dosage form can be a capsule, cachet or tablet itself, or it can be the appropriate number of any of these in package form. The quantity of active ingredient in a unit dose of composition may be varied or adjusted from 5 mg or less to 500 or more, according to the particular need and the activity of the active ingredient. The invention also includes the compounds in the absence of carrier where the compounds are in unit dosage form.

The following Examples illustrate the inven tion:- Example 1 N-(Diphenymethyl)-4-pyridinamine A mixture of 11.4 grams (0.05 mole) of benzilic acid and 4.7 grams (0.05 mole) of 4-aminopyridine was heated at 220"C for 3.5 hours. After cooling the mixture was dissolved in toluene and washed with 10% sodium carbonate solution and with 2N hydrochloric acid. The acidic extracts were basified with 5N sodium hydroxide and the resulting oil extracted into toluene. After drying over magnesium sulphate, the toluene was removed and the yellow oil was recrystallised from light petroleum (b.p. 80--100"C) giving 1.35 grams (10% yield) of the title compound, m.p. 152 to 154"C.

Example 2 N-(Diphenylmethyl)-4-pyridinamine 24.7 Grams (0.1 mole) of diphenylbromomethane and 29.4 grams (0.3 mole) of 4aminopyridine in 500 millilitres of toluene were heated under reflux with stirring for 20 hours.

The solid formed was filtered off and the toluene was extracted with 2N hydrochloric acid. The acid extracts were combined with the solid material and the solid was taken into solution by the addition of water and methanol. The alcoholic solution was basified with SN sodium hydroxide and extracted with toluene. After drying over magnesium sulphate, the solvent was removed and 8.01 grams of the title compound were obtained as the crude crystalline base, m.p. 148--50"C. The base was converted into its hydrochloride by solution in the minimum quantity of 2-propanol and addition of a solution of hydrogen chloride in dry ether. The hydrochloride was obtained as a colourless solid, m.p. 237--9"C.

Analysis: Found: C, 72.1 %; H, 5.9 %; N, 8.8 C,SH1 ,N . HCI. 1/4H2O requires: C, 71.75%; H, 5.84%; N, 9.3% EXAMPLE 3 N- [(di-pfluorophenyl)methyl j - 4-pyridinamine 8.85 Grams (0.03 mole) of chlorodi(p-fluoro- phenyl) methane and 11.75 grams (0.125 mole) of 4-aminopyridine in 250 millilitres of toluene were heated under reflux with stirring. After 8 hours, the reaction mixture was cooled and filtered to recover unreacted 4-aminopyridine.

The toluene solution was extracted with 2N hydrochloric acid and the acid extracts were basified wtih SN sodium hydroxide and extracted into toluene. After washing with water, the basic extracts were dried over magnesium sulphate and evaporated to give a 3.51 grams of a crystalline solid. The solid was recrystallised from toluene or a mixture of toluene and light petroleum (b.p. 6080o C) to afford 3.13 grams (28% yield) of colourless crystals of the title compound, m.p. 150 1530C.

Analysis: Found: C, 73.2 %; H, 4.9%; N, 9.4% C18H14F,N, requires: C, 72.95%; H, 4.8%; N, 9.20 EXAMPLE 4 N-[α(2-methylphenyl)benzyl] 4-pyridinamine 250 Millilitres of toluene containing 10.8 grams (0.05 mole) of chloro(phenyl-otolyl)- methane and 14.1 grams (0.15 mole) of 4aminopyridine were heated under reflux with stirring for 20 hours. The reaction mixture was cooled and the resulting organic layer and solid material were stirred with 2N hydrochloric acid. The toluene layer was removed and the gummy acidic extracts were basified with SN sodium hydroxide. The resulting oil was extracted into toluene and washed with water. After drying over magnesium sulphate, the solvent was removed and the residue was recrystallised from toluene to afford 3.58 grams (31% yield) of the title compound, m.p. 141 143 C. The product may be recrystallised from a mixture of benzene and light petroleum (b.p.

100-120 C).

Analysis: Found: C, 83.3%; H, 6.8%; N, 9.9% Cl9HlsN requires: C, 83.2%; H, 6.6%; N, 102% EXAMPLE 5 N- [a-(2-thienyl)benzyl]-4-pyridinamine 0.03 Mole of butyl lithium in hexane as a 15% w/w solution, was added dropwise to a stirred solution of 2.52 grams (0.03 mole) of thiophene in 50 millilitres of anhydrous ether under dry nitrogen. 4.55 Grams (0.025 mole) of benzylideneaminopyridine in 50 millilitres of dry ether was then added dropwise to the reaction mixture keeping the temperature below 10 C. The yellow precipitate obtained was stirred at room temperature for 6 hours and poured onto ice. The organic layer was separated and extracted with 2N hydrochloric acid and the acid extracts were combined with the aqueous layer. The resultant aqueous medium was basified with SN sodium hydroxide solution and then extracted with dichloromethane. After drying over magnesium sulphate, the solvent was removed to leave a solid which was recrystallised from a mixture of toluene and light petroleum (b.p. 100 - 1200C) to afford 2.67 grams of title compound, m.p. 125-126 C.

Analysis: Found: C, 72.0 %; H, 5.5%; N, 10.5% C,6H,4N,S requires C, 72.15%; H, 5.3%; N, 10.50/, The hydrochloride salt of the title compound, m.p. 224 C (decomposition), was prepared by dissolving the base in 2-propanol and treating with a solution of hydrogen chloride in dry ether.

Analysis: Found: C, 63.6%; H, 5.15%; N, 9.1 o, Cl,;Hl4N S . HCI requires C, 63.5%; H, 5.0 %; N, 9.25% EXAMPLE 6 N-[α(2-methoxyphenyl)benzyl]- 4pyridinanune 2.98 Grams (0.016 mole) of 4-benzylideneaminopyridine in 50 millilitres of dry ether were added dropwise to a stirred solution of 2-methoxyphenyl lithium (prepared from 0.03 mole of butyl lithium and 5.61 grams [0.03 molej of o-bromoanisole) in a mixture of ether and hexane at 0 C under nitrogen. The mixture was stirred at room temperature for 2 hours and then poured onto ice. The organic layer was separated and extracted with acid and the acid extracts were combined with the aqueous layer. The combined aqueous medium was basified with SN sodium hydroxide and extracted into dichloromethane. After drying over magnesium sulphate, the solvent was removed to leave a solid which yielded 2.3 grams of title compound, m.p. 143-5 C. The product was converted into its hydrobromide salt, m.p. 196-1980C, by solution in 2propanol and addition of hydrogen bromide in dry ether.

Analysis: Found: C, 61.6 o/O; H, 5.3%; N, 7.6% C19H18N2O . HBr requires C, 61.45%; H, 5.2%; N, 7.5% EXAMPLE 7 N-(α-[2-pyridyl]benzyl)-4-pyridinamine 4.55 Grams (0.025 mole) of 4-benzylideneaminopyridine in 50 millilitres of dry ether was added dropwise to a stirred solution of 2-pyridyl lithium (prepared from 0.03 mole of butyl lithium and 4.74 grams [0.03 mole] of 2-bromopyridine) in 100 ml. of hexane-ether cooled to -300C under nitrogen. A purple precipitate was formed which was stirred for 4 hours while allowing the product to warm up to room temperature. The mixture was poured onto ice and the organic layer was separated and extracted with 2N hydrochloric acid. The acid extracts were combined with the aqueous layer and the combined aqueous medium was basified with SN sodium hydroxide and extracted into dichloromethane.

After drying over magnesium sulphate, the solvent was removed to leave a solid which was recrystallized from a mixture of toluene and light petroleum (b.p. 10W120 C) to afford 2.27 grams of the title compound as free base, m.p. 114-115 C. The base was converted to its colourless dihydrobromide salt, m.p. 230 (decomposition), by dissolution in the minimum quantity of 2-propanol and adding a solution of hydrogen bromide in dry ether.

Analysis: Found: C, 48.3 % H, 4.23 ; N, 10.1% C17H15N3 . 2HBr requires C, 48.25% H, 4.05 4.US%; N, 9.9j, Example 8 N-(10,11-dihydro-5H-dibenzo[a,d]- cyclohepten-S-yl)A-pyridinamine 10.3 Grams (45 millimoles) of 5 - chloro 10,11 - dihydro - SH - dibenzo[a,d]cycloheptene and 7.05 grams (75 millimoles) of 4aminopyridine were heated together in 150 cc of dry toluene under reflux for 24 hours. After cooling, the toluene solution was decanted, washed twice with 75 cc of water and then washed twice with 2N hydrochloric acid (50 cc each time). A solid then precipitated at the interface. This solid (A) was collected and amounted to 1.42 grams. A gum also pre dpitated on the vessel walls, and was separated from the toluene and aqueous phases, which contained only unreacted starting materials.

This gum was washed with 2N hydrochloric acid and was then dissolved in chloroform, dried (MgSO4), and evaporated, leaving 1.34 grams of a foam. Extraction of this foam with a little chloroform left 1.0 gram of an insoluble solid (B).

Solid (B) was crystallised from ethyl acetate/ methanol, giving 0.58 grams of (N - 10,11 dihydro - 5H - dibenzo[a,d]cyclohepten - 5 - yl - 4 - pyridinamine)hydrochloride as colourless crystals, melting point 267-8 .

Analysis: Found: C, 74.7%; H, 6.2%; N, 8.4 C,0H1N2 . HC1 requires C, 74A%; H, 5.9%; N, 8.7% Further less pure material (0.77 grams) of melting point 263C was obtained by crystallisation of solid (A) from ethyl acetatemethanol.

Example 9 N-[α-butyl-2-thenyl]-4-pyridinamine To a stirred, cooled (10-20 C) a solution of 3.77 grams of 4-(2-thenylideneamino)pyridine in 100 millilitres of dry ether, a solution containing 0.025 mole butyl lith diphenyl acetamide in 50 millilitres of dry tetrahydrofuran stirred and cooled to 0 C.

When all diborane had been forrned, the reaction mixture was heated under reflux for 3 hours and then left overnight at room temperature. The mixture was cooled to 0 C and 10 millilitres of 6N hydrochloric acid was added. The tetrahydrofuran was removed at atmosphere pressure. The product was neutralised with SN sodium hydroxide, extracted into ether, dried (MgS04) and evaporated to an oil which solidified. After trituration with ether, 1.46 g (71% yield) of fine felted needles were obtained. The title compound was converted to its hydrochloride by solution in isopropyl alcohol/HCl/Et O. 1.18 Grams of product m.p. 2052070, were obtained.

Analysis: Found: C, 73.48%; H, 6.28%; N, 9.07% C19H18N2HCl requires C, 73.56%; H, 6.16%; N, 9.03% The N - (4 - pyridyl)diphenylacetamide starting material was prepared as follows: 9.4 Grams (0.1 mole) of 4-aminopyridine and 11.5 grams (0.05 mole) of diphenylacetyl chloride were stirred together at room temperature in 65 millilitres of pyridine for 4.5 hours. The resulting mixture was poured into water and extracted with toluene. The organic phase was separated, dried (MgSO4) and the toluene removed. The resulting solid was recrystallised from toluene yielding 10.9 g as phenyl - N - (4 - pyridinyl)benzene acetamide m.p. 166.5-168 C. The fumarate salt was prepared by dissolving equimolar quantities of the free base and fumaric acid in hot 2-propanol and allowing the product to crystallise.

Melting point 171-173 C.

Analysis: Found: C, 68.2%; H, 5.25%; N, 6.7% C,,6N20 . C4H40+ requires: C, 68.3%; H, 5.0 %; N, 6.7% EXAMPLE 11 N-([α-phenyl] -n-pentyl)4pyridinamine 0.03 Mole of butyl lithium in hexane as a 15% w/w solution was added dropwise to a stirred, cooled (- 100C) solution of 5.46 grams (0.03 mole) of 4-benzylideneamino pyridine in 10 millilitres of dry ether. The mixture was allowed to warm to room temperature and then poured onto ice and extracted with methylene chloride. The organic phase was separated and extracted with 2 N hydrochloric acid. The extracts were basified with 2 N sodium hydroxide and extracted into methylene chloride. The resulting methylene chloride solution was dried (MgS04) and decolourised with charcoal. The solvent was removed and the resulting light oil (5.75 grams) was crystallised and recrystallised from a toluene/petrol (60-80 C) mixture affording 2.36 grams of N - ([zz- phenyl] - n - pentyl) - 4 - pyridin amine, melting point 118-8.5 .

Analysis: Found: C, 79.94%; H, 8.40%; N, 11.58{ C 16H, 1N2 requires: C, 79.97%; H, 8.39%; N, 11.6609 The hydrochloride salt was prepared by dissolving the base in 2-propanol and treating with a solution of hydrogen chloride in dry ether. The salt had a melting point of 155.5- 157 C.

Analysis: Found: C, 69.13%; H, 7.60%; N, 10.03% C,6H,1N2Cl required: C, 69.43%; H, 7.650,ó; N, 10.12% EXAMPLE 12 N-([α-phenyl]-n-propyl)4-pyridinamine 5.4 Grams (0.03 mole) of 4-(benzylidine- amino) pyridine in 20 millilitres of dry ether was added to a stirred solution- of ethyl lithium (from 3.6 grams ethyl bromide and 0.42 grams of lithium) in 50 millilitres of ether under a nitrogen atmosphere at - 100C. The reaction mixture was allowed to warm to room; temperature and after 1 hour decomposed by the addition of water. A solid precipitated and was dissolved by adding toluene. The organic phase was separated and the basic material was extracted with 2N hydrochloric acid. The acid extracts were basified with 5N sodium hydroxide solution and extracted into toluene.

The toluene extracts were dried (MgS04) and the solvent was evaporated. The oil which remained was crystallised from a mixture of toluene and light petroleum (boiling point 6080 C) to afford 3.43 grams of white crystals of the title compound, melting point 112 to 114 C.

Analysis: Found: C, 79.2 %; H, 7.6%; N, 13.3 h C24H2cN, requires: C, 79.21%; H, 7.6%; N, 13 .2 A solution of the base in hot isopropanol was treated with hydrogen bromide in ether to give 3.33 grams of the title compound as its hydrobromide salt, melting point 190192 C.

Example 13 N- [(10,1 l-dihydro-SH-dibenzo [a,d ] cyclohepten-5-yl)methyl] -4-pyridinamine Diborane was generated by the dropwise addition over 12 hours at room temperature of a solution of 1.14 grams (30 millimoles) of sodium borohydride in 30 cc. of dry diglyme to a mixture of 6.2 cc. (7.1 grams, 50 millimoles) of redistilled boron trifluoride etherate and 6.2 cc of dry diglyme. The evolved diborane was swept in a slow stream of dry nitrogen into a solution of 3.14 grams (10 millimoles) of N - [(10,11 - dihydro - 5H dibenzo[a,d]cyclohepten - 5 - yl)carbonylj - 4 - pyridinamine in 50 cc. of dry tetrahydrofuran, cooled in ice. After complete addition of the borohydride solution, the generator flask was heated to 7080 for 2 hour to complete the genenation of diborane, which was swept into the reduction mixture as before. The reduction mixture was stirred at 0 for a further hour and was then heated to reflux for 3 hours, maintaining the nitrogen atmosphere. The apparatus was then sealed and allowed to cool overnight. 5 Millilitres of 6N hydrochloric acid were then added dropwise with care to the reduction mixture, resulting in vigorous hydrogen evolution. The acid solution was then evaporated to dryness to remove tetrahydrofuran and the residue was treated with 25 cc. of water, basified to pH9 with potassium carbonate, filtered, and the filtrate was extracted repeatedly with dichloromethane.

The combined organic extracts were dried using MgSO4 and evaporated, leaving 3.02 grams of a yellow oil whose IR spectrum contained no C=O absorption. This oil was taken up in a mixture of propan-2-ol, methanol and dichloromethane, made acid with ethereal hydrogen chloride, filtered and concenuated to 15 cc. On cooling N - [(10,11 - dihydro 5H - dibenzo [a,dj cyclohepten - S - yl)methyl] - 4 - pyridinamine, hydrochloride was deposited as colourless crystals (1.58 g, 42%), m.p.

245--6" with effervescence.

Analysis: Found: C, 75.0%; H, 6.3%; N, 8.1% C,1H,1N, . HC1 requires: C, 749%; H, 6.3%; N, 8.3% The N - [(10,11 dihydro - SH - dibenzo [a,d]cyclohepten - 5 - yl)carbonyl] - 4 pyridinamine starting material was prepared as follows: A solution of 4.7 grams (50 millilitres) of 4-aminopyridine in 50 cc of dry pyridine was treated dropwise at room temperature with a solution of 6.6 grams of 10,11 - dihydro - 5H dibenzo[a,d]cyclohepten - 5 - ylcarbonyl chloride (M. A. Davis, Stanley O. Winthrop, J. Steward, F. A. Sunahara, and F. Herr, J.

Medicin. Chem. 1963, 6, 2515) in 50 cc of toluene. After the exothermic reaction subsided the mixture was stirred at room temperature for 4 hours and was then poured into 30 cc of water. 100 millilitres of toluene were added and the phases were separated. The toluene phase was washed once with 100 cc of water, then the combined aqueous phases were back-extracted with toluene (3 x 100 cc).

The combined toluene solutions were dried (MgSO4) and evaporated, leaving an oily residue which was evaporated several times with further toluene and finally once with ethanol to remove residual pyridine, giving 8.45 grams of a yellow solid. This solid was crystallised from toluene (charcoal) giving offwhite crystals (4.78 g, 61%), m.p. 145---SC; second crop, off-white crystals (0.96 g, 12%), m.p. 14S7.50.

Both crops were indicated by infrared spectroscopy to contain a trace of carboxylic acid (C=O at 1700 cm), so both fractions were combined, dissolved in toluene (150 cc) and washed with 2N sodium hydroxide solution (3 X 25 cc) water (3 X 25 cc) and saturated sodium chloride solution (2 x 25 cc), and dried (MgSO4). The solution was filtered, concentrated to 50 cc, and allowed to crystaffise, giving 4.64 grams (57% yield) of N - [(10,11 dihydro - 5H - dibenzo[a,d]cyclohepten - 5 - yl)carbonyl] - 4 - pyridinamine as colourless crystals, m.p. 1489 .

Analysis: Found: C, 80.5 b; H, 6.0%; N, 9.0% C21HlSN2O requires: C, 80.2%,; H, 5.80,; N, 8.9Oó Example 14 N-(diphenylmethyl)-N-methyl 4-pyridinamine A solution of 2.6 grams (0.01 mole) of N (diphenylmethyl) - 4 - pyridinamine in 100 millilitres of dry tetrahydrofuran was added at -10 C to a solution of lithium diisopropylamine (prepared from 1.5 millilitres (0.01 mole) of diisopropylamine and butyl lithium in hexane (7.7 millilitres; 0.01 mole) at --20"C) in 100 millilitres of tetrahydrofuran, in an atmosphere of nitrogen. The solution was stirred at room temperature for 30 minutes, and then treated with 0.63 millilitres (0.01 mole) of methyl iodide and stirred at room temperature overnight. The solution was decomposed with 5 millilitres of water and evaporated to an oil which was dissolved in propan-2-ol. Acidification with ethereal hydrogen chloride followed by careful addition of ether gave 1.85 grams (56 jó yield) of N - (diphenylmethyl) - N - methyl - 4 pyridinamine hydrochloride monohydrate as white crystals, melting point 215--220"C.

Analysis: Found: C, 69.04%; H, 5.94%; N, 8.86% C19H18N2 # HCl # H2O requires: C, 69.4 %; H, 6.12%; N, 8.52% WHAT WE CLAIM IS: 1. A compound having the formula I

or a pharmaceutically acceptable acid addition salt thereof, wherein R1 and R2 together represent ArlQlower alkylene)-Ar'- where Arl and Ar2 are independently arylene or heteroarylene, or, when R1 and R2 are separate, one of R1 and R2 represents aryl or heteroaryl and the other one of R1 and R2 represents aryl, heteroaryl, ar(lower)alkyl or lower alkyl, R3 and R4 are independently hydrogen or lower alkyl and n represents o or 1.

2. A compound as claimed in Claim 1, wherein one of R1 and R2 represents aryl or heteroaryl and the other one of R1 and R2 is ar(lower)alkyl.

3. A -compound as claimed in Claim 2, wherein the said other one of R1 and R2 is phen(lower)alkyl.

4. A compound as claimed in Claim 2, wherein the said other one of R1 and R2 is berizyl.

5. A compound as claimed in any one of Claims 2 to 4, wherein one of R1 and R represents phenyl, (lower alkyl)phenyl, (lower alkoxy)phenyl, halophenyl, thienyl or pyridyl.

6. A compound as claimed in any one of Claims 2 to 5, wherein R3 and R4 are independently hydrogen or methyl.

7. A compound having the formula I

or a pharmaceutically acceptable acid addition salt thereof, wherein Rl and R together represent -Ar1-(lower alkylene)-Ar'- where Ar' and Ar2 are independently arylene or heteroarylene, or, when R' and R2 are separate, one of R1 and R2 represents aryl or heteroaryl and the other one of Rl and R2 represents aryl, heteroaryl or lower alkyl, Rs and R4 are independently hydrogen or lower alkyl and n represents 0 or 1.

8. A compound as claimed in Claim 7, wherein one of R1 and R2 is phenyl, (lower alkyl)phenyl, (lower alkoxy)phenyl, halophenyl, thienyl or pyridyl whilst the other of R1 and R2 is phenyl, (lower alkyl)phenyl, (lower alkoxy)phenyl, halophenyl, thienyl, pyridyl or lower alkyl or R1 and R2 together representphenylene - (lower alkylene) - phenylene-.

9. A compound as claimed in Claim 7 or 8, wherein R3 and K4 are independently hydrogen or methyl.

10. A compound having the formula

wherein Rl and R2 are independently aryl or heteroaryl and R and R4 are as defined in

**WARNING** end of DESC field may overlap start of CLMS **.

Claims

**WARNING** start of CLMS field may overlap end of DESC **. Analysis: Found: C, 69.04%; H, 5.94%; N, 8.86% C19H18N2 # HCl # H2O requires: C, 69.4 %; H, 6.12%; N, 8.52% WHAT WE CLAIM IS:

1. A compound having the formula I

7. A compound having the formula I

10. A compound having the formula

Claim 1, or a pharmaceutically acceptable add addition salt thereof.

11. A compound as claimed in Claim 10, wherein R1 and RZ are independently phenyl, (lower alkyl)phenyl, (lower alkoxy)phenyl, halophenyl, thienyl or pyridyl.

12. A compound as claimed in Claim 10 or 11, wherein R3 and R4 are independently hydrogen or methyl

13. N - (diphenylmethyl) - 4 - pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

14. N - [(di - p - fluorophenyl)methyl] 4 - pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

15. N - [a - (2 - methylphenyl)benzyl] 4 - pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

16. N - [ - (2 - thienyl)benzylj - 4 pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

17. N - [a - (2 - methoxyphenyl)benzyl] 4 - pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

18. N - [zz - (2 - pyridyl)benzyl] - 4 pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

19. N - (10,11 - dihydro - 5H - dibenzo [a,d] cyclohepten - 5 - yl) - 4 - pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

20. N - [ - butyl - 2 - thenyl] - 4 pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

21. N - (2,2 - diphenylethyl) - 4 - pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

22. N - [( - phenyl) - n - pentyl] - 4 pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

23. N - ([a - phenyl] - n - propyl) - 4 pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

24. N - [(10,11 - dihydro - 5H - dibenzo [a,d] - cyclohepten - 5 - yl)methyl] - 4 pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

25. N - (diphenylmethyl) - N - methyl - 4 pyridinamine or a pharmaceutically acceptable acid addition salt thereof.

26. A process for the preparation of a compound as claimed in Claim 1, wherein (a) a compound having the formula III

(wherein Rl and RZ are as defined in Claim 1) is reacted under elevated temperature with a 4aminopyridine having the formula IV

(where R is as defined in Claim 1) to form a compound having the formula

(where Rl, R2 and R" are as defined in Claim 1) or (b) a compound having the formula

(where R1 and K4 are as defined in Claim 1) is treated with a reactive organometallic compound whose organo moiety is R2 as defined in Claim 1; or (c) an amine having the formula VII

(where R', R2 and n are as defined in Claim 1), another one of W, X and Y represents a group having the formula

(where R" is as defined in Claim 1) and the remaining one of W, X and Y represents K3 subject to the proviso that, when Y represents R" as defined above, then R3 is lower alkyl); or (d) a Schiffs base having the formula XII or XIII

(wherein Rl, R2 and K4 are as defined in Claim 1) is reduced; or (e) an amide having the formula XIV

or an acid addition salt thereof (wherein Rl, R2, R3 and Rl are as defined in Claim 1) is reduced to form a compound where n is 1, and, if desired, a free base form of the compound having formula I is converted into a pharmaceutically acceptable acid addition salt thereof or an acid addition salt form of a compound having formula I is converted into its free base form.

27. A process as claimed in Claim 26, wherein one of R1 and R2 represents aryl or heteroaryl and the other one of R' and R is ar(lower)alkyl.

28. A process as claimed in claim 27, wherein the said other one of Rl and R' is as defined in claim 3 or 4

29. A process as claimed in Claims 27 or 28, wherein one of R' and R2 represents phenyl, (lower alkyl)phenyl, (lower alkoxy)phenyl, halophenyl, thienyl or pyridyl.

30. A process as claimed in any one of Claims 27 to 29, wherein R3 and Rl are independently hydrogen or methyl.

31. A process as claimed in Claim 26, wherein R1 and R2 are as defined in Claim 7.

32. A process as claimed in Claim 31, wherein R1 and R2 are as defined in Claim 8.

33. A process as claimed in Claim 31 or 32, wherein R3 and K4 are as defined in Claim 9.

34. A process for the preparation of a compound as claimed in Claim 10 wherein (a) a compound having the formula III

(wherein Rl and RZ are as defined in Claim 10) is reacted under elevated temperature with a 4-aminopyridine having the formula IV

(where R' is as defined in Claim 10j to form a compound having the formula

(where Rl, R- and R' are as defined in Claim 10) or (b) a compound having the formula

(where R' and R4 are as defined in Claim 10) is treated with a reactive organometallic compound whose organo moiety is Re as defined in Claim 10; or (c) an amine having the formula VII

as a free base or acid addition salt (where in formulae VII, VIII and IX any one of W, X and Y represents a group having the formula R'--CH(R2))- (where R' and R2 are as defined in Claim 10), another one of W, X and Y represents a group having the formula

(where R' is as defined in Claim 10 and the remaining one of W, X and Y represents K' as defined above subject to the proviso that, when Y represents Ra as defined above, then R3 is lower alkyl); or (d) A Schiff's base having the formula XII

(wherein R1, R2 and Rt are as defined in Claim 10) is reduced; and, if desired, a free base form of the compound having formula I is converted into a pharmaceutically acceptable acid addition salt thereof or an acid addition salt form of a compound having formula I is converted into its free base form.

35. A process as claimed in Claim 34, wherein R1 and R2 are as defined in Claim 11.

36. A process as claimed in Claim 34 or 35, wherein Rs and R4 are independently hydrogen or methyl.

37. A process as claimed in Claim 34 or 36, wherein step (a) is carried out where R' and R2 are phenyl.

38. A process as claimed in any one of Claims 26 to 30, wherein step (b) is carried out where the reactive organo-metallic com pound is a lithium compound having the formula R2Li.

39. A process as claimed in any one of Claims 31 to 33, wherein step (b) is carried out where the reactive organometallic compound is a lithium compound having the formula R2Li.

40. A process as claimed in any one of Claims 34 to 36, wherein step (b) is carried out where the reactive organometallic compound is a lithium compound having the formula R2Li.

41. A process as claimed in any one of Claims 26 to 30, wherein step (c) is carried out by reacting a compound having the formula

(where n is 0 and Hal is halogRn) with an amine having the formula IV.

42. A process as claimed in any one of Claims 31 to 33, wherein step (c) is carried out by reaction of a compound having the formula

(where n is 0 and Hal is halogen) with an amine having the formula IV

43. A process as claimed in any one of Claims 34 to 36, wherein step (c) is carried out by reaction of a compound having the formula

(where n is zero and Hal is halogen) with an amine having the formula IV

44. A process as claimed in any one of Claims 26 to 30, wherein step (e) is carried out using diborane as reducing agent.

45. A process as claimed in any one of Claims 31 to 33, wherein step (e) is carried out using diborane as reducing agent.

46. A process as claimed in Claim 34, carried out substantially as described herein with reference to any one of Examples 1 to 7 herein.

47. A process as claimed in Claim 31, carried out substantially as described herein with reference to any one of Examples 8 to 12 herein.

48. A process as claimed in Claim 26, carried out substantially as described herein with reference to either one of Examples 13 and 14 herein.

49. A compound as claimed in Claim 1, whenever prepared by a process as claimed in any one of Claims 26 to 30, 38, 41, 44 and 48.

50. A compound as claimed in Claim 7, whenever prepared by a process as claimed in any one of Claims 31 to 33, 39, 42, 45 and 47.

51. A compound as claimed in Claim 10, whenever prepared by a process as claimed in any one of Claims 34 to 37, 40, 43 and 46.

52. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 6 and 49 and a pharmaceutically acceptable carrier.

53. A pharmaceutical composition comprising a compound as claimed in any one of Claims 7 to 9 and 50 and a pharmaceutically acceptable carrier.

54. A pharmaceutical composition comprising a compound as claimed in any one of claims 10 to 12 or 51 and a pharmaceutically acceptable carrier.

55. A pharmaceutical composition comprising a compound as claimed in any one of claims 13 to 18 and a pharmaceutically acceptable carrier.

56. A pharmaceutical composition comprising a compound as claimed in any one of Claims 19 to 23 and a pharmaceutically acceptable carrier.

57. A pharmaceutical composition comprising a compound as claimed in either one of Claims 24 and 25 and a pharmaceutically acceptable carrier.

58. A compound having the formula

or an acid addition salt thereof, wherein Rl, R2, R3 and K4 are as defined in Claim 1.

59. A compound having the formula

or an acid addition salt thereof, wherein R', R2, R and K4 are as defined in Claim 7.

60. N - (4 - pyridyl)diphenylacetamide or an acid addition salt thereof.

61. N - [(10,11 - dihydro - SH - dibenzo [a,d] cyclohepten - 5 - yl)carbonyl] - 4 - pyridinamine or an acid addition salt thereof.